<DOC>
	<DOCNO>NCT02252016</DOCNO>
	<brief_summary>This randomize , multi-site , placebo-controlled trial fix dose combination ( FDC ) grazoprevir ( MK-5172 ) 100 mg + elbasvir ( MK-8742 ) 50 mg participant chronic Hepatitis C Virus ( HCV ) genotype ( GT ) 1 , GT4 GT6 inherit blood disorder . The primary hypothesis proportion participant treat grazoprevir+elbasvir achieving Sustained Virologic Response ( SVR ) 12 week end study therapy ( SVR12 ) great reference rate 40 % .</brief_summary>
	<brief_title>Grazoprevir ( MK-5172 ) Elbasvir ( MK-8742 ) Combination Chronic Hepatitis C Virus ( HCV ) Genotypes 1 , 4 , 6 ( MK-5172-065 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>HCV GT1 , GT4 , GT6 sickle cell anemia , thalassemia , hemophilia/von Willebrand disease cirrhosis noncirrhotic human immunodeficiency virus ( HIV ) coinfected infected HIV female non childbearing potential , male female us acceptable method ( ) contraception evidence decompensated liver disease coinfected hepatitis B malignancy â‰¤5 year prior sign inform consent except adequately treat basal cell squamous cell skin cancer situ cervical cancer hepatocellular carcinoma ( HCC ) evaluation HCC clinicallyrelevant drug alcohol abuse within 12 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>